Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: Results from Japan

Antiviral Therapy

Volumn 4, Issue 2, 1999, Pages 61-68

  Matsumoto, Keizo ^a  

^a NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SIALIDASE INHIBITOR; VIRUS SIALIDASE; ZANAMIVIR;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HUMAN; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SORE THROAT; TOPICAL DRUG ADMINISTRATION;

ADULT; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; GUANIDINES; HUMANS; INFLUENZA, HUMAN; NEURAMINIDASE; PYRANS; SIALIC ACIDS; ZANAMIVIR;

EID: 0032766880     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Kitamoto O. Therapeutic effectiveness of amantadine hydrochloride in influenza A2. Double-blind studies. Japanese Journal of Tuberculosis and Chest Disease 1968; 15:17-26
2. von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, Van Phan T, Smythe ML, White HF, Oliver SW et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363:418-423.
3. Ryan DM, Ticehurst J, Dempsey MH & Penn CR. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrobial Agents and Chemotherapy 1994; 38:2270-2275.
4. Woods JM, Bethell RC, Coates JA, Healy N, Hiscox SA, Pearson BA, Ryan DM, Ticehurst J, Tilling J, Walcott SM et al. 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrobial Agents and Chemotherapy 1993; 37:1473-1479.
5. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD & Hussey EK. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental influenza. Journal of the American Medical Association 1996; 275:295-299.
6. Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, Bohnen AM, Hirst HM, Keene O & Wightman K. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. GG167 Influenza Study Group. New England Journal of Medicine 1997; 337:874-880.
7. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections Lancet 1998; 352:1877-1881.
8. Infectious Agents Surveillance Report 1995, Vol. 16, No. 12.